Cardiac Biomarkers Market Scope & Overview:

To Get More Information on Cardiac Biomarkers Market - Request Sample Report

Cardiac Biomarkers Market Size was valued at USD 18.51 Billion in 2023 and is expected to reach USD 63.21 billion by 2032, growing at a CAGR of 14.64% over the forecast period 2024-2032.

This report delivers a statistical analysis of the global Cardiac Biomarkers Market, focusing on the growing prevalence and incidence of cardiovascular diseases across regions. Features diagnostic test volumes, prescription trends, and production and supply chain key biomarker assays in Troponin and BNP. The report also analyzes healthcare spending patterns, segmented by public, private, and out-of-pocket expenditure related to cardiac diagnostics. It also addresses the best places to be for changing regulatory approvals and the growing acceptance of more modern biomarker technology. Collectively, these insights reflect a comprehensive, data-driven perspective on the evolving market dynamics that dictate the direction of clinical adoption, market penetration, and investment in cardiac biomarker diagnostics over the decade. The cardiac biomarkers are important diagnostic tools for diagnosing heart muscle injury and cardiovascular health which is evident for their better utilization in the early diagnosis and management of heart diseases.

The U.S. Cardiac Biomarkers Market has witnessed robust growth from USD 6.37 billion in 2023 to an Impressive USD 21.57 billion by 2032 with a significant CAGR of 14.52% over the forecast period. Factors like high prevalence of cardiovascular diseases, introduction of high-sensitivity diagnostic assays, and robust healthcare infrastructure are responsible for this growth. In addition to that, favorable reimbursement policies and ongoing technological improvements in point-of-care testing are also contributing to the growth of the market in the region. Cardiovascular diseases (CVDs) remain the leading cause of mortality across the world, with millions of deaths every year being attributed to heart-related diseases according to the World Health Organisation. The U.S. Centers for Disease Control and Prevention (CDC) highlights that heart disease is the leading cause of death in the United States, accounting for one in every five deaths.

Market Dynamics

Drivers

• Rapid increase in global cardiovascular disease prevalence has significantly driven the demand for faster, more accurate diagnostic cardiac biomarker solutions.

According to WHO, cardiovascular diseases (CVDs) are the leading cause of death in the world, accounting for nearly 18 million deaths annually. There are two main factors driving this scary statistic which are lifestyle changes such as sedentary lifestyle, consumption of unhealthy diets, global rise in tobacco and alcohol consumption and chronic stress. And with such drivers developing further in the contemporary world mainly within metropolitan locations respiratory illness are getting to be much more frequent and intense. Cardiac biomarkers are crucial since they provide the rapid, non-invasive, and highly reliable diagnosis of myocardial injury in these settings. Such biomarkers troponins, creatine kinase-MB, and natriuretic peptides provide vital diagnostic and prognostic information, allowing clinicians to act promptly. Prognosis is more favourable and complications and health care costs are minimized if a disease is diagnosed early.  Furthermore, an aging global population, with higher susceptibility to CVDs due to weakened cardiovascular systems and associated comorbidities like diabetes or hypertension, adds to the rising demand. This means that approaches that utilize rapid diagnostic tools are increasingly in demand all around the world, which has placed cardiac biomarkers in the centre of cardiology workflows. Emergency departments, ICUs, and outpatient settings application of aids clinical decision making, and life-saving. These newfound tools will only become more effective as biomarker sensitivity and automation continue to improve. The global market for cardiac biomarker diagnostics is expected to continue to grow as cardiovascular disease burden grows and the demand for quick and precise diagnostics rises triple orders that make it a prominent growth driver within the market.

Restrain

• High cost of advanced cardiac biomarker tests limits accessibility in low- and middle-income regions, impacting adoption and diagnostic equity.

The affordability of cardiac biomarker testing remains a major challenge, especially in resource-constrained settings. High-sensitivity assays and multiplex platforms used for advanced cardiac biomarker tests require significant investment in proprietary reagents, specialized instruments, and trained personnel. These costs are exorbitant for a number of healthcare facilities in LMICs, contributing to a lack of cardiac biomarker diagnostic options available or a complete lack in public hospitals and primary care units. Even in high-income countries, cost considerations can restrict test usage, particularly where reimbursement policies are unclear or vary across insurers. As a result, early detection and better heart services are not there for millions of people, especially those in remote or less-served regions. Inevitably, failure to provide biomarker testing leads to delays in diagnosis or misdiagnosis, which is associated with detrimental long-term clinical outcomes and increasing healthcare costs. Furthermore, there are limited tests available in LMICs, as diagnostic manufacturers prefer testing in profitable markets with strong reimbursement systems. In addition, this cost barrier limits the clinical application of cardiac biomarkers and contributes to global health inequity. While numerous NGOs and global health organizations are working hard to improve access to diagnostic tests, cost continues to be an obstacle to widespread adoption. Without policy changes, subsidies, or the development of low-cost alternatives, the potential of cardiac biomarkers to transform cardiovascular care will remain underutilized in many parts of the world.

Opportunities

• Expansion of AI-integrated diagnostics is opening new pathways for advanced cardiac biomarker analytics and precision cardiovascular care solutions worldwide.

The integration of artificial intelligence (AI) and machine learning in cardiac diagnostics is revolutionizing how cardiac biomarkers are interpreted and applied.  By processing every data point of biomarker data in realtime, AI will identify hidden patterns and provide predictive insights that not only allow the diseases where they can be detected early but also allow customized treatment of cardiovascular diseases. Algorithms can now interpret troponin levels alongside patient history and clinical parameters to classify the risk of myocardial infarction, lowering false positives and invasive assessments by unnecessary catheterizations. Increasing preference of hospitals and diagnostic labs towards these AI-based platforms, paired with the biomarker assay, will further fuel the market growth. Furthermore, cloud-based diagnostics and remote AI analysis are becoming increasingly feasible, especially with the rise of telecardiology. This helps to enhance the access to advanced diagnostics in rural or underprivileged regions. The ecosystem is enabling AI-cardiology innovations and commercial partnerships from start-ups and tech giants alike. Regulatory authorities are starting to recognize the role AI can play in diagnostics and are establishing adaptive frameworks that enable accelerated approval of products. The integration of AI with health devices and point-of-care tests allows for continuous monitoring of biomarkers and real-time management of care. Aging AI models will evolve multi-biomarker analysis and real-time risk scoring to be more definitive and dynamic for cardiac care. The convergence of AI and cardiac biomarkers is opening unique pathways to broaden the reach, decrease the burden, and enhance the clinical value of cardiac biomarker diagnostics on a worldwide scale and steering the industry towards a new frontier of digital and data-oriented micro- and macro-health policy.

Challenges

• High complexity of clinical validation and regulatory approval delays the commercialization of novel cardiac biomarker technologies.

The path from biomarker discovery to market adoption is complex and time-consuming, often taking years of rigorous validation and regulatory scrutiny. Unlike standard diagnostic tools, cardiac biomarkers must undergo extensive clinical trials to prove their sensitivity, specificity, and predictive value across various patient populations and clinical scenarios. Regulatory agencies such as the FDA and EMA require robust data on analytical validity, clinical utility, and real-world performance before granting approval. These requirements, although essential for patient safety, significantly increase the time and cost of development. Start-ups and small biotech firms, which are often at the forefront of innovation, struggle with these barriers due to limited funding and clinical trial resources. Even after regulatory approval, achieving market adoption requires guideline inclusion, payer acceptance, and physician education, each of which is an additional hurdle. Moreover, when multiple biomarkers are used in combination (e.g., in panels or multiplex assays), the complexity of validation multiplies, making it difficult to achieve standardization and scalability. Regulatory landscapes also vary significantly across regions, adding further complexity for companies aiming for global market penetration. These challenges slow down the translation of cutting-edge research into practical, widely accessible diagnostic solutions. As a result, many promising cardiac biomarkers remain confined to academic research or specialized labs, never reaching the broader clinical market. Overcoming this challenge requires streamlined regulatory frameworks, stronger public-private partnerships, and greater investment in translational research to ensure innovative biomarkers can effectively enter and impact the healthcare system.

Segmentation Analysis

By Type

The troponin segment continues to lead the cardiac biomarkers market, holding the largest revenue share 33%, in 2023. This is mainly attributed to troponins' unmatched specificity and sensitivity for identifying myocardial injury, rendering them the gold standard for diagnosing AMI and ACS. The excellent diagnostic performance of troponin assays has been supported by widespread clinical validation and extensive use in healthcare environments globally. High-sensitivity troponin assays have been one of the major growth drivers of the segment. These new tests are capable of identifying even slight increases in troponin levels within hours of disease onset, allowing for timely diagnosis and prompt decision-making. The capacity to rapidly rule in or rule out cardiac events minimizes unnecessary admissions, decreases emergency department stays, and enhances outcomes. The American College of Cardiology and the European Society of Cardiology have included high-sensitivity troponin testing in their guidelines, further solidifying its clinical significance.

Government programs and healthcare policies also drive the troponin segment's growth. For instance, the CDC's focus on early detection and treatment of heart attacks has resulted in greater testing for troponins in emergency rooms. The increasing incidence of cardiovascular diseases worldwide, especially among the aging population, also drives demand for accurate diagnostic instruments. As per the CDC, more than 800,000 Americans have a heart attack each year, and troponin testing plays an important role in timely diagnosis.

By Application

The application of cardiac biomarkers in diagnosing and managing acute coronary syndrome (ACS) remains the largest segment in 2023, accounting for over 55% of the market’s revenue share. This is due to the pivotal function played by biomarkers, particularly troponins, in making swift and accurate diagnoses of ACS, which includes conditions such as unstable angina and myocardial infarction. Considering the severe morbidity and mortality linked with ACS, early intervention and detection become crucial for enhancing patient outcomes. All government health agencies across the globe, the CDC included, rank early diagnosis of ACS as a top priority because of its immense health impact. According to the CDC, in America alone, the agency notes 1.5 million ACS-related hospitalizations every year, highlighting the need for effective diagnostic measures. Cardiac biomarkers assist in the discrimination between non-cardiac and cardiac chest pain, limiting inappropriate interventions and directing appropriate therapy like thrombolysis, percutaneous coronary intervention, or surgery.

The incorporation of high-sensitivity troponin assays into clinical practice has transformed ACS management. These assays allow clinicians to identify myocardial injury hours after symptom onset, enabling swift triage, risk stratification, and treatment. Serial troponin testing for suspected ACS is recommended by the American Heart Association, which has greatly enhanced diagnostic accuracy and decreased hospitalization.

By End-Use

Laboratory testing segment accounted for 65% revenue share of the cardiac biomarkers market in 2023. This leadership is driven by the need for high-precision, high-quality, and standardized test environments pivotal to accurate diagnosis & management of patients. Central lab comes with a specific environment; high-throughput capability = owing to modern instrumentation; making it appropriate for hospitals, reference lab, and healthcare network The main benefit of laboratory testing, as opposed to point-of-care testing, is the higher analytical sensitivity and specificity. High-sensitivity troponin assays, being laboratory-based tests providing accurate biomarker quantification, are needed to accurately diagnose subtle circumstances of myocardial injury, monitor disease progression or help guide treatment strategy. Such tests are usually combined with an set of other tests into a complete diagnostic panel to provide a comprehensive diagnosis for heart diseases.

One propelling factor which is responsible for the dominance of laboratory testing is its regulatory compliance and quality assurance. They functioned within a strict regulatory environment such as CLIA in the U.S., which enforced standardized processes, traceability, and high-quality outputs from accredited establishments. And the need for reliability is even more critical for complicated cases, serial testing and research purposes.

Regional Analysis

North America region dominated the cardiac biomarkers market in 2023 with 42% share of the global revenue. It is supported by factors such as a well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and a considerable prevalence of cardiovascular diseases. For instance, cardiac biomarker testing is commonly used in the United States for early detection and management of heart conditions, particularly due to the availability of hospitals, laboratories, and diagnostic centers. Cardiovascular disease is a major cause of morbidity and mortality in the U.S., and according to the CDC, heart disease is the leading cause of death, associated with 697 000 deaths per year. The increasing geriatric population, along with lifestyle risk factors like obesity, smoking, and hypertension, are some of the major things that boost the growth of the advanced diagnostic tools. Government initiatives like the CDC’s Million Hearts program aim to prevent heart attacks and strokes, further promoting the use of biomarkers in routine care.

On the other hand, the Asia-Pacific region is expected to grow at the fastest CAGR over the forecast period. China, India, and Southeast Asia are undergoing rapid economic development and urbanization, and lifestyle changes have resulted in a rising prevalence of cardiovascular disease (CVD). Countries are expanding investments in healthcare infrastructure, opening access to diagnostics, and mobilizing public awareness campaigns. For instance, India’s National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) emphasizes early detection through biomarker testing. China’s government has prioritized non-communicable disease management, including cardiovascular health, with substantial funding allocated for diagnostic infrastructure expansion.

Do You Need any Customization Research on Cardiac Biomarkers Market - Enquire Now

Key Players

• Abbott (i-STAT 1 System, Afinion 2 Analyzer)

• Roche Diagnostics (Elecsys Troponin T high-sensitive, Elecsys NT-proBNP)

• Siemens Healthineers (High-Sensitivity Troponin I Assay, BNP and NT-proBNP Assays)

• Beckman Coulter (Access BNP Immunoassay, Access NT-proBNP Immunoassay)

• bioMérieux (VIDAS NT-proBNP2, VIDAS High Sensitive Troponin I)

• QuidelOrtho (Quidel Triage Cardiac Panel, Quidel Triage Cardio3 Panel)

• Response Biomedical (RAMP NT-proBNP Test, RAMP Troponin I Test)

• Ortho Clinical Diagnostics (VITROS Troponin I ES Assay, VITROS NT-proBNP Assay)

• Boditech Med (ichroma Troponin I, ichroma NT-proBNP)

• Radiometer Medical (AQT90 FLEX Troponin T, AQT90 FLEX NT-proBNP)

• Randox Laboratories (Evidence Investigator Troponin I, Biochip Array Technology for BNP)

• DiaSys Diagnostic Systems (CardioPhase hsCRP, CardioPhase Troponin I)

• Fujirebio (Lumipulse G BNP, Lumipulse G Troponin I)

• Tosoh Bioscience (AIA-PACK BNP, AIA-PACK Troponin I)

• HyTest Ltd. (Troponin I Antibodies, BNP Antibodies)

• Diazyme Laboratories (Diazyme BNP Assay, Diazyme Troponin I Assay)

• Wondfo Biotech (Finecare Troponin I Rapid Test, Finecare NT-proBNP Rapid Test)

• Trinity Biotech (CardioTrol Troponin I, CardioTrol CK-MB)

• Alere (now part of Abbott) (Triage BNP Test, Triage Troponin I Test)

• Nova Biomedical (Stat Profile Prime Plus Troponin I, Stat Profile Prime Plus BNP)

Recent Developments​

• In October 2023, Mindray unveiled new high-sensitivity cardiac biomarkers, troponin I (hs-cTnI) and NT-proBNP, enhancing the detection and management of cardiovascular diseases.